The use of a mechanism-based irreversible LSD1 inhibitor, GSK-LSD1, which increased H3K4me2 levels and efficiently blocked TGF-β signalling, rules out an enzymatic role of LSD1 in basal SSc myofibroblast maintenance. This evidence concerns the gene KDM1A and systemic sclerosis.